Rhophylac (Human Rho(D) Immune Globulin) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Rhophylac. Always confirm against the full prescribing information.
100 interactions
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Human Rho(D) immune globulin.
Level 2 evidence
Aducanumab
The risk or severity of adverse effects can be increased when Human Rho(D) immune globulin is combined with Aducanumab.
Level 2 evidence
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Human Rho(D) immune globulin.
Level 2 evidence
Alirocumab
The risk or severity of adverse effects can be increased when Alirocumab is combined with Human Rho(D) immune globulin.
Level 2 evidence
Amivantamab
The risk or severity of adverse effects can be increased when Human Rho(D) immune globulin is combined with Amivantamab.
Level 2 evidence
Anifrolumab
The risk or severity of adverse effects can be increased when Human Rho(D) immune globulin is combined with Anifrolumab.
Level 2 evidence
Ansuvimab
The risk or severity of adverse effects can be increased when Human Rho(D) immune globulin is combined with Ansuvimab.
Level 2 evidence
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Human Rho(D) immune globulin.
Level 2 evidence
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Human Rho(D) immune globulin.
Level 2 evidence
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Human Rho(D) immune globulin.
Level 2 evidence
Asfotase alfa
The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Human Rho(D) immune globulin.
Level 2 evidence
Atezolizumab
The risk or severity of adverse effects can be increased when Atezolizumab is combined with Human Rho(D) immune globulin.
Rhophylac (Human Rho(D) Immune Globulin) has 162 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Rhophylac (Human Rho(D) Immune Globulin) has 0 major, 1 moderate, and 161 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Rhophylac. Always confirm against the full prescribing information.